Attendee search 

Jean Yao, PhD, with 20+ years of extended experience in the areas of biology, medical research, and medical industry, has held various positions at Mayo Clinic and University of Minnesota. She funded Med Qiao Group LLC as for the Bridge between US and China in life science. Med Qiao provides business consulting services that include investment funding, market analysis, intellectual property protection, clinical trial arrangement, product approval application, China branch or division establishment as well as marketing, promotion, distribution and onsite manufacturing of medical products.

PhysioCue is a medical device company that has developed an anti-hypertension medical device, clinically shown to immediately reduce the high blood pressure of hypertensive patients. This device is non-invasive and works by controlled cold therapy with the carotid artery baroreceptor reflex. Unlike drug treatments, our PhysioCue therapy device is efficient, safe, easy to use, non-invasive, and has none of the side effects associated with anti-hypertensive drugs. We also develop mobile Health device.

PhysioCue’s Mechanism of Action is the body’s natural baroreflexive system which provides important monitoring and feedback for blood flow throughout the body. It activates baroreceptors in the wall of the carotid artery which stimulate the afferent and efferent pathways of the automatic nervous system. To lower excessive blood pressure the brain responds by modulating efferent pathways, which relaxes the blood vessels, slows the heart rate and reduces fluid in the body. These actions reduce the afterload on the heart by decreasing arterial resistance, which improves the heart’s ability to pump blood to the tissues. The increase in parasympathetic tone and decrease in sympathetic drive results in the restoration of sympathetic-vagal balance which reduces excessive blood pressure and improves cardiac structure and function.

PhysioCue’s video has been published on YouTube http://youtu.be/A1bMjg5a3MY ,

The Addario Lung Cancer Medical Institute (ALCMI), founded in 2008 as a 501c(3) non-profit organization, is a patient-centric, international research consortium driving research otherwise not possible, evidenced by ALCMI's current clinical studies CASTLE, INHERIT EGFR T790M, Genomics of Young Lung Cancer and others. ALCMI overcomes barriers to collaboration via a world-class team of investigators from 21+ institutions in the U.S., France, Italy, Spain and U.K., supported by dedicated research infrastructures such as centralized project management, tissue banks and data systems. ALCMI directly facilitates research by combining scientific expertise found at leading academic institutions with patient access through our network of community cancer centers – accelerating novel research advancements to lung cancer patients.